Steven L Barriere
Overview
Explore the profile of Steven L Barriere including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
814
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Stryjewski M, Lentnek A, ORiordan W, Pullman J, Tambyah P, Miro J, et al.
BMC Infect Dis
. 2014 Jun;
14:289.
PMID: 24884578
Background: Staphylococcus aureus bacteremia is a common infection associated with significant morbidity and mortality. Telavancin is a bactericidal lipoglycopeptide active against Gram-positive pathogens, including methicillin-resistant S. aureus (MRSA). We conducted...
12.
Rubinstein E, Stryjewski M, Barriere S
Infect Drug Resist
. 2014 May;
7:129-35.
PMID: 24876786
Background: Hospital-acquired pneumonia (HAP) is the most common health care-associated infection contributing to death. Studies have indicated that there may be differences in the causative pathogens and outcomes of ventilator-associated...
13.
Barriere S, Stryjewski M, Corey G, Genter F, Rubinstein E
BMC Infect Dis
. 2014 Apr;
14:183.
PMID: 24708675
Background: Existing data are not consistently supportive of improved clinical outcome when vancomycin dosing regimens aimed at achieving target trough levels are used. A retrospective, post hoc, subgroup analysis of...
14.
Barriere S
Future Microbiol
. 2014 Jan;
9(3):281-9.
PMID: 24450506
Hospital-acquired bacterial pneumonia (HABP) is the second most common nosocomial infection in the USA and the leading cause of mortality among hospital-acquired infections. An increasing proportion of HABP cases are...
15.
Corey G, Kollef M, Shorr A, Rubinstein E, Stryjewski M, Hopkins A, et al.
Antimicrob Agents Chemother
. 2014 Jan;
58(4):2030-7.
PMID: 24419353
U.S. Food and Drug Administration draft guidance for future antibiotic clinical trials of bacterial nosocomial pneumonia recommends the use of diagnostic criteria according to American Thoracic Society/Infectious Diseases Society of...
16.
Ero M, Harvey N, Harbert J, Janc J, Chin K, Barriere S
J Thromb Thrombolysis
. 2013 Oct;
38(2):235-40.
PMID: 24132401
Telavancin is approved in the United States, Canada, and Europe (At the time of submission, the telavancin European marketing authorization for nosocomial pneumonia was suspended until Theravance provides evidence of...
17.
Stryjewski M, Barriere S, Rubinstein E, Genter F, Lentnek A, Magana-Aquino M, et al.
Int J Antimicrob Agents
. 2013 Jul;
42(4):367-9.
PMID: 23891527
No abstract available.
18.
Krause K, Blais J, Lewis S, Lunde C, Barriere S, Friedland H, et al.
Diagn Microbiol Infect Dis
. 2012 Oct;
74(4):429-31.
PMID: 23083812
In phase 3 studies of the efficacy of telavancin for the treatment of hospital-acquired pneumonia, 704 Gram-positive and 627 Gram-negative aerobic bacterial pathogens were obtained at baseline from 1503 patients....
19.
Stryjewski M, Potgieter P, Li Y, Barriere S, Churukian A, Kingsley J, et al.
Antimicrob Agents Chemother
. 2012 Aug;
56(11):5476-83.
PMID: 22869571
TD-1792 is a first-in-class glycopeptide-cephalosporin heterodimer that exhibits bactericidal activity against Gram-positive pathogens. We conducted a randomized, double-blind, active-control, phase II trial in patients with complicated skin and skin structure...
20.
Stryjewski M, Barriere S, ORiordan W, Dunbar L, Hopkins A, Genter F, et al.
J Antimicrob Chemother
. 2012 Mar;
67(6):1496-502.
PMID: 22416054
Background: Telavancin is approved in the USA and Canada for the treatment of Gram-positive complicated skin and skin structure infections (cSSSIs) based on the results of the Phase 3 Assessment...